HS Optimus Holdings Limited: Key Updates on Proposed Medicorp Acquisition and SGX-ST Listing Notice
Summary of Key Points
- HS Optimus Holdings Limited has entered into a Sales and Purchase Agreement (SPA) to acquire 7,500 ordinary shares in Medicorp Sdn Bhd, representing 30% of Medicorp’s total issued share capital.
- The consideration for the acquisition is to be satisfied by issuing up to 185,185,185 Consideration Shares and up to 185,185,185 Option Consideration Shares.
- On 10 June 2026, HS Optimus Holdings received a Listing and Quotation Notice (LQN) from the Singapore Exchange Securities Trading Limited (SGX-ST) for the listing and quotation of these shares, contingent upon compliance with SGX-ST’s listing requirements.
- The LQN is not an endorsement of the merits of the shares, the acquisition, or the company itself.
- The acquisition is still subject to conditions outlined in the SPA and may not necessarily be completed.
- Shareholders and potential investors are advised to exercise caution and await further announcements from the company regarding the progress and completion of the acquisition.
Detailed Report for Investors
HS Optimus Holdings Limited, a company incorporated in Singapore, has announced a significant corporate development that could potentially impact its share price and attract investor interest. The company has entered into a Sales and Purchase Agreement (SPA) with Lee Rui Ren for the acquisition of a 30% stake in Medicorp Sdn Bhd, a move that positions HS Optimus Holdings to expand its portfolio and possibly enhance its future earnings profile.
The proposed acquisition involves the purchase of 7,500 ordinary shares in Medicorp Sdn Bhd, representing 30% of Medicorp’s total issued share capital. To facilitate this transaction, HS Optimus Holdings will issue up to 185,185,185 Consideration Shares and up to 185,185,185 Option Consideration Shares to the seller, subject to compliance with SGX-ST’s listing requirements. The issuance of these shares, if completed, will significantly expand the company’s share base and potentially dilute existing shareholdings, which is an important factor for shareholders to consider.
The company announced that on 10 June 2026, it received a Listing and Quotation Notice (LQN) from SGX-ST, confirming the conditional approval for the listing and quotation of the new shares. However, investors should note that the LQN is not a validation of the merits of the Consideration Shares, the Option Consideration Shares, the Proposed Acquisition, or the company itself. It is merely an indication that the shares can be listed, provided the company meets the exchange’s requirements.
Potential Impact and Shareholder Considerations
- The acquisition, if successfully completed, could lead to a strategic expansion of HS Optimus Holdings’ business operations and revenue streams.
- The issuance of a substantial number of new shares could have a dilutive effect on current shareholders’ holdings, which may impact the share price depending on market perception and the value attributed to Medicorp Sdn Bhd.
- The acquisition is not yet completed; it remains subject to the fulfillment of conditions stipulated in the SPA. There is no certainty or assurance at this stage that the transaction will go through.
- Shareholders and potential investors are strongly advised to monitor further announcements from HS Optimus Holdings, as the completion or failure of the acquisition could be price-sensitive and materially affect the company’s valuation.
- Until the acquisition is finalized, investors should exercise caution when trading the company’s securities and consult professional advisers if in doubt.
Company Statement and Regulatory Disclosure
The announcement has been reviewed by the company’s sponsor, UOB Kay Hian Private Limited, but has not been examined or approved by SGX-ST. SGX-ST assumes no responsibility for the contents or accuracy of the announcement. Any queries regarding the company’s sponsor can be directed to Mr. Lance Tan, Senior Vice President, at UOB Kay Hian Private Limited.
Conclusion
This update represents a potentially price-sensitive development for HS Optimus Holdings Limited. The progress and eventual outcome of the proposed Medicorp acquisition, along with the issuance and listing of a substantial number of new shares, could materially affect the company’s share price. Investors are urged to stay informed and vigilant regarding further company disclosures.
Disclaimer
This article is based on information provided by HS Optimus Holdings Limited and does not constitute investment advice or a recommendation to buy or sell any securities. Investors should conduct their own due diligence and consult with professional advisers before making any investment decisions. The completion of the acquisition is not guaranteed and may be subject to change.
中文版本
HS Optimus Holdings Limited 宣布拟收购 Medicorp Sdn Bhd 并获得新加坡交易所上市通知
报告要点
- HS Optimus Holdings Limited已签署协议，拟收购Medicorp Sdn Bhd 7,500股普通股，占Medicorp总股本的30%。
- 收购对价将通过发行最多185,185,185股对价股份和最多185,185,185股期权对价股份支付。
- 2026年6月10日，公司收到新加坡交易所（SGX-ST）的上市和报价通知（LQN），前提是符合交易所的相关上市要求。
- LQN并非对对价股份、期权对价股份、拟收购事项或公司本身的认可。
- 收购仍受SPA协议中的条件约束，目前尚不确定能否完成。
- 公司提醒股东和潜在投资者在交易公司证券时需保持谨慎，并关注公司后续公告。
投资者详细解读
HS Optimus Holdings Limited作为新加坡注册公司，宣布了一项可能影响股价的重要企业发展。公司与Lee Rui Ren签署协议，拟收购Medicorp Sdn Bhd 30%的股份，这有助于公司扩展业务板块并提升未来盈利能力。
拟收购涉及Medicorp Sdn Bhd 7,500股普通股，占其总股本30%。公司将发行最多185,185,185股对价股份和最多185,185,185股期权对价股份，作为收购对价。若交易完成，公司股本将大幅扩张，现有股东持股比例将被稀释，这对股东来说是重要影响。
公司于2026年6月10日收到SGX-ST的上市和报价通知（LQN），确认相关股份可在满足交易所要求后上市。但投资者应注意，LQN并不代表对拟收购事项或公司本身的认可，仅为相关股份上市的前提。
潜在影响与股东关注事项
- 收购若成功完成，将有助于公司业务扩展和收入增长。
- 大量新股发行可能导致现有股东持股比例被稀释，进而影响股价，市场对Medicorp价值的评估也会产生影响。
- 收购尚未完成，仍需满足SPA协议规定的条件。当前无法保证交易一定完成。
- 建议股东和投资者密切关注公司后续公告，因收购完成与否均可能对公司估值产生重大影响。
- 在收购完成前，投资者应谨慎交易公司证券，并咨询专业顾问。
公司声明与监管披露
本公告已由公司赞助商UOB Kay Hian Private Limited审阅，但未获SGX-ST正式审查或批准，SGX-ST不对公告内容及准确性负责。如有疑问可联系公司赞助商相关负责人。
结论
本次更新对HS Optimus Holdings Limited而言属于潜在重要影响股价的事件。拟收购Medicorp进展及大规模新股发行上市，均可能对公司股价产生实质性影响。投资者应保持关注并密切留意公司后续公告。
免责声明
本文基于HS Optimus Holdings Limited公告内容，仅供参考，不构成任何投资建议。投资者应自行进行尽职调查，并在作出投资决策前咨询专业顾问。收购事项尚未完成，相关情况可能发生变动。
